These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 8678066)

  • 1. Controlled study on the improvement of quality of life in elderly hemodialysis patients after correcting end-stage renal disease-related anemia with erythropoietin.
    Moreno F; Aracil FJ; Pérez R; Valderrábano F
    Am J Kidney Dis; 1996 Apr; 27(4):548-56. PubMed ID: 8678066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement of nutritional status in patients receiving maintenance hemodialysis after correction of renal anemia with recombinant human erythropoietin.
    Tarng DC; Huang TP; Doong TI
    Nephron; 1998; 78(3):253-9. PubMed ID: 9546682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of generic and specific quality-of-life measures in hemodialysis patients treated with erythropoietin. The Canadian Erythropoietin Study Group.
    Laupacis A; Wong C; Churchill D
    Control Clin Trials; 1991 Aug; 12(4 Suppl):168S-179S. PubMed ID: 1663853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease.
    Ifudu O; Feldman J; Friedman EA
    N Engl J Med; 1996 Feb; 334(7):420-5. PubMed ID: 8552143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between protein-energy wasting in adults with chronic hemodialysis and the response to treatment with erythropoietin.
    González-Ortiz A; Correa-Rotter R; Vázquez-Rangel A; Vega-Vega O; Espinosa-Cuevas Á
    BMC Nephrol; 2019 Aug; 20(1):316. PubMed ID: 31412807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients.
    Beusterien KM; Nissenson AR; Port FK; Kelly M; Steinwald B; Ware JE
    J Am Soc Nephrol; 1996 May; 7(5):763-73. PubMed ID: 8738812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: a parallel, randomized, double blind study.
    Pérez-Oliva JF; Casanova-González M; García-García I; Porrero-Martín PJ; Valenzuela-Silva CM; Hernández-Montero T; Lagarde-Ampudia M; Casanova-Kutsareva Y; Avila-Albuerne Y; Vargas-Batista A; Bobillo-López H; Herrera-Valdés R; López-Saura PA;
    BMC Nephrol; 2005 May; 6():5. PubMed ID: 15910687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of quarterly average achieved hematocrit with mortality in dialysis patients: a time-dependent comorbidity-adjusted model.
    Messana JM; Chuang CC; Turenne M; Wheeler J; Turner J; Sleeman K; Tedeschi P; Hirth R
    Am J Kidney Dis; 2009 Mar; 53(3):503-12. PubMed ID: 19185402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology.
    Moreno F; Sanz-Guajardo D; López-Gómez JM; Jofre R; Valderrábano F
    J Am Soc Nephrol; 2000 Feb; 11(2):335-342. PubMed ID: 10665941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severity of AIDS and the response to EPO in uremia.
    Ifudu O; Matthew JJ; Mayers JD; Macey LJ; Brezsnyak W; Reydel C; McClendon E; Surgrue T; Rao S; Friedman EA
    Am J Kidney Dis; 1997 Jul; 30(1):28-35. PubMed ID: 9214398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease.
    Ballal SH; Domoto DT; Polack DC; Marciulonis P; Martin KJ
    Am J Kidney Dis; 1991 Jan; 17(1):29-33. PubMed ID: 1986567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of erythropoietin before the initiation of dialysis and its impact on mortality.
    Fink J; Blahut S; Reddy M; Light P
    Am J Kidney Dis; 2001 Feb; 37(2):348-55. PubMed ID: 11157377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of anemia with quotidian hemodialysis.
    Rao M; Muirhead N; Klarenbach S; Moist L; Lindsay RM
    Am J Kidney Dis; 2003 Jul; 42(1 Suppl):18-23. PubMed ID: 12830439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subjective quality of life assessment in hemodialysis patients at different levels of hemoglobin following use of recombinant human erythropoietin.
    McMahon LP; Dawborn JK
    Am J Nephrol; 1992; 12(3):162-9. PubMed ID: 1415377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low dose intravenous ascorbic acid for erythropoietin-hyporesponsive anemia in diabetic hemodialysis patients with iron overload.
    Lin CL; Hsu PY; Yang HY; Huang CC
    Ren Fail; 2003 May; 25(3):445-53. PubMed ID: 12803508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients.
    Kuriyama S; Tomonari H; Yoshida H; Hashimoto T; Kawaguchi Y; Sakai O
    Nephron; 1997; 77(2):176-85. PubMed ID: 9346384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone marrow changes following treatment of renal anemia with erythropoietin.
    Horina JH; Schmid CR; Roob JM; Winkler HM; Samitz MA; Hammer HF; Pogglitsch H; Krejs GJ
    Kidney Int; 1991 Nov; 40(5):917-22. PubMed ID: 1762296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of high-flux hemodialysis on renal anemia.
    Ayli D; Ayli M; Azak A; Yüksel C; Kosmaz GP; Atilgan G; Dede F; Abayli E; Camlibel M
    J Nephrol; 2004; 17(5):701-6. PubMed ID: 15593038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of the treatment with human recombinant erythropoietin on anemia in children with end-stage kidney failure. French multicenter study].
    Sinnassamy P; Andre JL; Treize G; Leroy B
    Arch Fr Pediatr; 1993 Mar; 50(3):201-8. PubMed ID: 8338412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy of recombinant human erythropoietin in the treatment of anemia in hemodialysis patients: influence of dosing regimen, iron status, and serum aluminum.
    Tsai JC; Lai YH; Tsai ZY; Chien LJ; Tsai JH
    Gaoxiong Yi Xue Ke Xue Za Zhi; 1991 Mar; 7(3):126-35. PubMed ID: 1865507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.